Viehbacher worries about his future as diabetes sales hit Sanofi's 3Q
This article was originally published in Scrip
Executive Summary
Amid speculation that CEO Christopher Viehbacher is worried about his job, French pharma major Sanofi reported third quarter sales that were slightly weaker than expected at €8.781bn. Mr Viehbacher said the "challenging US diabetes price environment" was likely to continue to impact sales throughout 2015.